Sector ratings Gan & Lee Pharmaceuticals.

Equities

End-of-day quote Shanghai S.E. Other stock markets 20/05/2026			5-day change	1st Jan Change
55.15 ^CNY	+0.79%		-5.40%	-18.98%

05-15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GAN & LEE PHARMACEUTICALS.	4.83B		-			-
REGENERON PHARMACEUTICALS, INC.	66.11B		BBB
UCB	52.82B		AA
SAMSUNG BIOLOGICS CO.,LTD.	41.34B		BBB
CSL LIMITED	34.22B		A
BIOGEN INC.	27.73B		AA
INCYTE CORPORATION	19.39B		AA
MODERNA, INC.	19.09B	-	BBB	-		-
INNOVENT BIOLOGICS, INC.	17.59B		AAA
SWEDISH ORPHAN BIOVITRUM AB	16.17B		AA
ALTEOGEN INC.	12.85B		CCC
BRIDGEBIO PHARMA, INC.	13.36B	-	BB	-		-
AXSOME THERAPEUTICS, INC.	11.87B	-	BBB	-		-
BIOMARIN PHARMACEUTICAL INC.	9.7B		BBB			-
KRYSTAL BIOTECH, INC.	8.9B	-	B	-		-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	7.1B	-	BB	-		-	-
GRIFOLS, S.A.	6.82B		BB
3SBIO INC.	6.15B		A
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	5.77B	-	-	-		-	-
HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.	5.46B	-	B	-	-	-	-	-
Average	19.36B		A
Weighted average by Cap.			A